Pacific Biosciences is trading at $1.37 (+7.03%) as biotech strength, XBI’s 2.06% rise, and a broader risk-on backdrop support the move.
- No company-specific announcement dated August 25, 2026 was identified; latest listed releases are August 5 earnings, CEO transition, and Vega update.
- The August 25 webinar is educational, not a disclosed financial or regulatory catalyst.
- Reduced 2026 guidance and delayed cash-flow breakeven remain relevant but do not clearly explain today’s gain.